The opinion in support of the decision being entered today
is not binding precedent of the Board.
UNITED STATES PATENT AND TRADEMARK OFFICE
__________
BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
__________
Ex parte BOJIDAR M. STANKOV
__________
Appeal 2007-3261
Application 09/854,802
Technology Center 1600
__________
Decided: September 20, 2007
__________
Before DEMETRA J. MILLS, LORA M. GREEN, and RICHARD M.
LEBOVITZ, Administrative Patent Judges.
LEBOVITZ, Administrative Patent Judge.
DECISION ON APPEAL
This is a decision on appeal from the final rejection of claims 16-18
and 20-24. We have jurisdiction under 35 U.S.C. § 6(b). We affirm.
STATEMENT OF CASE
Melatonin (N-acetyl-5-methoxytryptamine) is a naturally-occurring
compound which is known to induce and improve the depth and quality of
sleep (Spec. 2). Because of its short half-life in the blood, exogenously
administered melatonin has been found to be insufficient to regulate sleep
(Spec. 2-3). To address this problem, melatonin has been administered in
Page: 1 2 3 4 5 6 7 8 9 10 11 Next
Last modified: September 9, 2013